Expression of the cell-cycle regulatory proteins (cyclins D 1 and E) in endometrial carcinomas: correlations with hormone receptor status, proliferating indices, tumor suppressor gene products (p53, pRb), and clinicopathological parameters

Purpose of investigation: This study aimed to investigate the immunohistochemical expression of cyclins D1 and E in normal, hyperplastic and neoplastic endometrium, and their correlation with proliferative activity and clinicopathological features.

Methods: We carried out immunohistochemical techniques on archived material of formalin-fixed paraffin-embedded tissues using the antibodies against the cyclins D1 and E, PR-ER, p53, Ki67 (MIB1) and pRb with the streptavidin-biotin-peroxidase method in a total of 20 cases of normal endometrium, 32 cases of hyperplastic endometrium and 66 cases of endometrial carcinomas.

Results: Cyclin D1 and E immunoreactivity was observed in the nuclei of tumour cells in 18.2% and 39.1%, respectively, of the cases of endometrial carcinomas. Cyclin D1 labelling index was not significantly correlated with any of the clinicopathologic parameters examined. However, there was a significant correlation between the cyclin E labelling index and histological grade of carcinoma (p = 0.00096), which increased significantly with histological grades of malignancy. We also detected a significant correlation between cyclin E and PCNA (p < 0.0001) as well as with the tumor suppressor genes p53 and pRb (p = 0.052 and 0.0002, respectively) in endometrioid endometrial carcinoma.

Conclusion: Our results indicate that cyclin E overexpression may be involved in the development and/or proliferation and differentiation of human endometrioid endometrial carcinoma. Immunoexpression of cyclin D1 does not appear to be associated with cell-cycle progression in the benign or malignant endometrium.

Cyclin Dl; Cyclin E; p53, pRb; Endometrial carcinoma

[1] American Cancer Society: "Cancer Facts and Figures 2001". Atlanta, GA. Am. Cancer Soc., 2001.

[2] Srivatse P.J., Cliby W., Keeney G.L., Suman V.J., Harsen W.S., Ziesmer S.C. et al.: "Expression of nm23/nucleoside diphosphate kinase A protein in endometrial carcinoma". Gynecol. Oncol., 1997, 66 (2), 238.

[3] Milde-Langosch K., Bamberger AM., Goemana C., Rossing E., Rieck G., Kelp B., Loning T.: "Expression of cell cyclin regulatory proteins in endometrial carcinomas: correlations with hormone receptor status and clinicopathologic parameters". Cancer Res. Clin. Oncol., 2001, 127 (9), 544.

[4] Nikaido T., Li S.F., Shiozawa T., Fujii S.: "Co-abnormal expression of cyclin DI and p53 protein in human uterine endometrial carcinomas". Cancer, 1996, 78 (6), 1248.

[5] Lees E.: "Cyclin dependent kinase regulation". Current Opin. Cell. Biol., 1995, 7 (6), 773.

[6] Barbieri F., Cagnoli M., Ragni N., Pedulla F., Foglia G., Alama A.: "Expression of cyclin D 1 correlates with malignancy in human ovarian tumors". Br. 1 Cancer, 1997, 75 (9), 1263.

[7] Jares P., Fernandez P.L., Campo E., Nadal A., Bosh F., Aiza G. et al.: "PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas". Cancer Res., 1994, 54 (17), 4813.

[8] Gillett C., Fanti V., Smith R., Fisher Ch., Barteck J., Barnes D. et al.: "Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining". Cancer Res., 1994, 54 (7), 1812.

[9] Ohtsubo M., Theodoras A.M., Schumacher J., Roberts J.M., Pagano M.: "Human cyclin E, a nuclear protein for the GI to S phase transition". Mol. Cell. Biol., 1995, 15 (5), 2612.

[10] Koff A., Giordano A., Desai D., Yamashita K., Harper J.W., Elledge S. et al.: "Formation and activation of a cyclin E-cdk2 complex during the G 1 phase of the human cell cycle". Science, 1992, 257 (5077), 1689.

[11] Jiang W., Zhang Y.J., Kahn S.M., Hollstein M.C., Santella R.M., Lu S.H. et al.: "Altered expression of the cyclin DI and retinoblastoma genes in human oesophageal cancer". Proc. Natl. Acad. Sci. USA, 1993, 90 (12), 9026.

[12] Creasman W.T.: "Announcement FIGO stages: Revision". Gynecol Oneal., 1988, 35, 125.

[13] Scully R.E., Bonfiglio T.A., Kurman R.J., Silverberg S.G., Wilkinson E.J.: "WHO's Histological Typing of Female Genital Tract Tumors". 2"'ed., Berlin: Springer Verlag, 1998, 406.

[14] Ito K., Sasano H., Yoshida Y., Sato S., Yajima A.: "Immunohistochemical study of cyclin D 1 and E, and cyclin dependent kinase (cdk) 2 and 4 in human endometrial carcinoma". Anticancer Res., 1998, 18 (13A), 1661.

[15] Segreti E., Movotny D.B., Soper J.T., Mutch W.T., Creasman K.S., McCarty J.: "Endometrial cancer: histologic correlates of immunohistochemical localization of progesteron and oestrogen receptor" Obstet. Gynecol., 1989, 73, 780.

[16] Sung C.J., ZhengY., Quddus M.R., Kang X., Zhang Z.F., Laychland S.C. et al.: "p53 as a significant prognostic marker in endometrial carcinoma". Int. J. Gynecol. Cancer, 2000, 10 (21), 119.

[17] Joffe O.B., Papadimitriou J.C., Drachanberg C.B.: "Correlation of proliferative indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic and malignant endometrium". Hum. Pathol., 1998, 29 (10), 1150.

[18] Joachim E.E., Goussia A.C., Kitsiou E.G., Charalampopoulos K., Mermiga E., Stefanaki S.: "Immunohistochemical expression of retinoblastoma gene product in normal, hyperplastic and malignant endometrium. Correlation with p53 protein, c-erbB-2, hormone receptor status, and proliferative activity". Dis. Markers, 2000, 18 (3), 1.

[19] McCluggage W.G.: "Recent advances in immunohistochemistry in gynaecological pathology". Histopathology, 2002, 40 (4), 309.

[20] Quddus M.R., Latkovich P., Castellani W.J., Sung J., Steinhoff M.M. et al.: "Expression of cyclin DI in normal, metaplsatic, hyperplastic endometrium and endometrioid carcinoma suggests a role in endometrial carcinogenesis". Arch. Pathol. Lab. Med., 2002, 126(4), 459.

[21] Wang T.C., Cardiff R.D., Zukerberg L., Less E., Arnold A., Schmidt E.V.: "Mammary hyperplasia and carcinoma in MMTV-cyclin D1 trangenic mice". Nature, 1994, 369 (6482), 669.

[22] Fanti V., Richards M.A., Lammie G.A., Johnstone G., Allen D.. Gregory W. et al.: "Gene amplification on chromosome band l l q l 3 and oestrogen receptor status i n breast cancer". Eur. J . Cancer, 1990, 26 (4), 423.

[23] Nielsen A.L., Nyholm H.C.: "The combination of p53 and age predict cancer specific in advanced stage of endometrial carcinoma of endometrioid type. An immunohistochemical examination of growth fraction: Ki67, MIB l , and PC lO; suppressor oncogene protein p 185 and age, hormone treatment, stage, and histologic grade". Eur. J. Obstet. Gynecol. Rep. Biol., 1996, 70 (1), 79.

[24] Shiozawa T., Li S.F., Nakayama K., Nikaido T., Fujii S.: "Relationship between the expression of cyclins/cyclin-dependent kinases and sex steroid receptors, Ki67 in normal human endometrial glands and stoma during the menstrual cycle". Mo!. Hum. Reprod., 1996, 2(10), 745.

[25] Zukerberg L.R., Y nag W.I., Gadd M., T hor A.D., Koerner F.C., Schmidt E.V. et al.: "Cyclin D 1 (PRAD 1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene". Mod. Pathol., 1995, 8 (5), 560.

[26] Kurzrock R., Ku S., Talpaz M.: "Abnormalities in the PRAD l (cyclin DI/bcl-1) oncogene are frequent in cervical and vulvar squamous cell carcinoma lines". Cancer, 1995, 75 (2), 584.

[27] Barbieri F., Cagnoli M., Ragni N., Foglia G., Bruzzo C., Pedulla F., et al.: "Increased cyclin DI expression is associated with features of malignancy and disease recurrence in ovarian tumors". Clin. Cancer Res., 1999, 5 (7), 1837.

[28] Lee C.R.. Yamamoto S., Morimura K., Wanibuchi H.. Nishsaka N., Ikemoto S. et al.: "Significance of cyclin DI overexpression in Iransitional cell carcinomas of the urinary bladder and its correlation with histopathologic features". Cancer, 1997, 79 (4), 789.

[29] Callender T., El Naggar A.K., Lee M.S., Frankerthaler R., Luna M.A., Batsakis J.G. et al.: "PRADI (CCNDI)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma". Cancer, 1994, 74 (1), 152.

[30] Jares P., Rey M.J., Fernandez P.L., Campo E., Nadal A., Munoz M et al.: "Cyclin DI and retiuoblastoma gene expression in human breast carcinoma: correlation with tumor proliferation and oestrogen receptor status". J. Pathol., 1997, 182 (2), 160.

[31] Xiong T., Zhang H., Beach D.: "Retinoblastoma gene product in tumorigenesis". Cell., 1993, 71, 505.

[32] Jiang W., Zhang Y.J., Kahn S., Hollstein M.C., Santella R., Lu S.H et al.: "Altered expression of the cyclin DI and retinoblastoma genes in human oesophageal cancer". Prac. Natl. Acad. Sci. USA, 1993, 90 (19), 9026.

[33] Heffner H.M., Freedman A.N., Asiwathan J.E., Lele S.B.: "Prognostic significance of p53, PCNA and c-erb-B-2 in endometrial carcinoma". Eur. J. Gynaecol. Oncol., 1999, 20 (1), 8.

[34] Wang D.A., Konishi I., Koshiyama M., Mandai, Nambu Y., Ishikawa Y. et al.: "Expression of c-erbB-2 protein and epidermal growth factor receptor in endometrial carcinomas. Correlation with clinicopathologic and sex steroid status". Cancer, 1993, 72 (1), 2628.

[35] Session D.R., Lee G.S., Choi J., Wolgemuth D.J.: "Expression of cyclin E in gynaecological m心gnancies". Gynecol. Oncol., 1999, 72 (1), 32.

[36] Milde-Langosh K.M., Hagen M., Bamberger A.M., Loning T.:"Expression and prognostic value of the cell cycle regulatory proteins,Rb, p l6MST1, p21WAF1, p27KIP1, cyclin E and cyclin D2, in ovarian cancer". Int. J. Gynaecol. Pathol., 2003, 22 (2), 168.

[37] Keyomarsi K., O'Leary N., Molnar G., Lees E., Finger! H.J., Pardee A.B.: "Cyclin E, a potential prognostic marker for breast cancer". Cancer Res., 1994, 54, 380.

[38] Milde-Langosch K., Bamberger A.M., Mothner C.C., Rieck G., Loning T.: "Expression of cell cycle regulatory proteins Rb, pl6/MTSI, p27/KIPI, p21/WAF!, cyclin DI and cyclin E in breast cancer: correlations with expression of activating protein-I family members". Int. J. Cancer, 2000, 87 (4), 468.

[39] Courjal F., Louason G., Speiser P., Katsaros D., Zeillenger R., Theillet Ch.: "Cycline gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin DI in breast and cyclin E in ovarian tumors". Int. J. Cancer, 1996, 69 (4), 247.

[40] Li S.F., Shiozawa T., Nakayama K., Nikaido T., Fujii S.: "Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma". Cancer, 1996, 77 (2), 321.

[41] Semeczuk A., Marzec B., Roessner A., Jakowicki J.A., Wojcierowski J., Schneider-Stock R.: "Loss of heterozygosity of the retinoblastoma gene is correlated with the altered pRb expression in human endometrial cancer". Vzrchows Arch., 2002, 441 (6), 577.

[42] Classon M., Harlow E.:'The retinoblastoma tumor suppressor gene in development and cancer". Nature Rev. Cancer, 2002, 2 (12), 910.

[43] Skomedal H., Kristensen G.B., Nesland J.M., Borrensen-Dale A.L., Trope C., Holm R.: "TP53 alterations in relation to the cell cycle associated proteins p21, cyclin D l -CDK4, RB, MDM2, and EGFR in cancer of the uterine corpus". J. Pathol., 1999, 187 (51), 556.

[44] Tsuda H., Yamamoto K., Inoue T., Uchiyama I., Umesaki N.: "The role of p16 cyclin D/CDK-pRB pathway in the tumorigenesis of endometrioid type endometrial carcinoma". Br. J. Cancer, 2000, 82(3), 675.